SCHEMBL12293236

SCHEMBL12293236

COC(=O)[C@H](NC(=O)OCc1ccccc1)[C@@H](NC(=O)OC(C)(C)C)c1ccc(OC)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.54
SYK P43405 1/20 0.51
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
ACHE P22303 1/20 0.49
TRPM8 Q7Z2W7 1/20 0.47
KLK5 Q9Y337 1/20 0.46
CACNA1B Q00975 1/20 0.45
CNR2 P34972 1/20 0.45
PLAU P00749 1/20 0.45
CTSL P07711 3/20 0.44
CTSS P25774 3/20 0.44
CTSK P43235 2/20 0.44
CYP3A4 P08684 2/20 0.44
ALDH1A1 P00352 1/20 0.44
TSHR P16473 1/20 0.44
PPARA Q07869 2/20 0.43
MAPT P10636 1/20 0.43
TP53 P04637 1/20 0.43
CTSD P07339 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12292863 1.00 ATM (0.54) ATMSYKCA1CA2ACHE
SCHEMBL13723080 0.94 ATM (0.56) ATMSYKCA1CA2ACHE
SCHEMBL12292858 0.94 ATM (0.56) ATMSYKCA1CA2ACHE
SCHEMBL12292859 0.94 ATM (0.56) ATMSYKCA1CA2ACHE
SCHEMBL12292809 0.92 SYK (0.56) ATMSYKTRPM8KLK5CTSL
SCHEMBL12292806 0.92 SYK (0.56) ATMSYKTRPM8KLK5CTSL
SCHEMBL14404880 0.89 ATM (0.47) ATMSYKCA1CA2ACHE
SCHEMBL14404875 0.89 ATM (0.47) ATMSYKCA1CA2ACHE
SCHEMBL13722612 0.89 SYK (0.47) ATMSYKCA1CA2ACHE
SCHEMBL13723091 0.89 SYK (0.47) ATMSYKCA1CA2ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076285-B2 Lysobactin amides AICURIS GMBH & CO. KG (DE) 2011-12-13 US disclosed
US-8076285-B2 Lysobactin amides AICURIS GMBH & CO. KG (DE) 2011-12-13 US disclosed
EP-2007794-B1 LYSOBACTIN AMIDES AICURIS GMBH & CO KG (DE) 2011-09-14 EP disclosed
US-20090203582-A1 LYSOBACTIN AMIDES BAYER HEALTHCARE AG (DE) 2009-08-13 US disclosed
US-20090203582-A1 LYSOBACTIN AMIDES BAYER HEALTHCARE AG (DE) 2009-08-13 US disclosed
WO-2007118691-A1 LYSOBACTIN AMIDES AICURIS GMBH & CO. KG (DE) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203582-A1 LYSOBACTIN AMIDES AADAT, HAMP, DLST ATM 4224/4885SYK 2789/4885CA1 4760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.